Mark Bachleda
CIK 1887762 · Chief Commercial Officer · last filed 2026-06-12
Mark Bachleda is a Chief Commercial Officer who has filed 6 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for LYEL, was dated Jun 12, 2026. Across all open-market trades the lifetime net is +$24.7K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
201 HASKINS WAY, SUITE 101
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYEL | Director | — | $13.62 | — | $0 | 2 | 2026-06-12 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Chief Commercial Officer | 55 | $17.60 | $968 | $24.7K | 4 | 2023-03-20 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2025-06-11 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-03-20 | Galera Therapeutics, Inc. (GRTX) Delisted | Buy (P) | +11,000 | $24.7K | EDGAR |
| 2023-02-28 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-02 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-12 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).